Introduction
Chronic myelogenous leukemia is an hematopoietic stem cell disorder that accounts for 15-20% of all leukemias in adults. 1 The hallmark of the disease is the Philadelphia chromosome, 2 which is a result of the (9;22)(q34;q11) translocation. 3 Multiple experimental models established the product of the translocation, the deregulated Bcr-Abl tyrosine kinase, as the causative leukemogenic agent (for review, see Refs 4 and 5) . The central role of Bcr-Abl in the pathogenesis of CML have made it a particularly attractive target for drug therapy. 6 The Abl kinase inhibitor imatinib mesylate proved to be safe and effective in phase I clinical studies for CML and Ph + acute lymphoblastic leukemia (ALL). 7, 8 These results were confirmed in phase II international multicenter studies which have been published recently.
Taken together, these data confirm the remarkable efficacy of imatinib as a single agent for all stages of CML. However, two major concerns arise from the clinical studies: 40% of the patients treated for chronic phase CML after interferon failure remain predominantly Ph + . A recent analysis suggests these patients have a higher risk of relapse. 9 Primary and secondary resistance to imatinib causes frequent relapses in blast crisis patients. 10, 89, 90 Correspondence Work from several groups have revealed various mechanisms of resistance both in vitro 11 and in vivo. [12] [13] [14] [15] The emergence of resistance to imatinib is not a surprise, particularly in advanced phase CML where molecular abnormalities in addition to Bcr-Abl are undoubtedly present. Resistance to antineoplastic agents has been studied extensively and this research has revealed a complex scenario of mechanisms similar to those reported with imatinib. 16 The occurrence of resistance led to the use of multiple antineoplastic agents with differing mechanisms of action. Based on these considerations, several groups investigated in vitro combinations of imatinib with various anti-leukemic agents.
Insights from in vitro cytotoxicity studies -conventional chemotherapeutic agents
In vitro studies demonstrate that Bcr-Abl has anti-apoptotic activity and renders leukemic cells resistant to chemotherapy. 17, 18 Inhibition of Bcr-Abl expression by antisense oligonucleotides reverses the suppression of apoptosis and makes CML cells susceptible to apoptois by antileukemic drugs. 19 McGahon et al 19 showed that the anti-apoptotic effect of Bcr-Abl is dependent on Bcr-Abl kinase activity. Therefore, it was hypothesized that kinase inhibition by imatinib would also act as a chemo-sensitizer. Indeed, Fang et al 20 showed that imatinib significantly increased cytosine arabinoside (ara-C) or doxorubicin-induced apoptosis of Bcr-Abl positive cell lines.
Several groups have published in vitro combination studies using imatinib and conventional chemotherapeutic agents. [21] [22] [23] Table 1 lists the results for data obtained with comparable parameters (identical cell line (K562), same drug or drug class). All results were generated using tetrazolium-based cell line proliferation assays (MTT assay). 24 These groups determined the inhibition of proliferation after continuous exposure to the combination drugs for 2 days (Topaly et al . The data were analyzed by the median effect method based on the isobologram equation 25 (Topaly) , the isobologram by hand method (Thiesing) (Kano) . The methodical differences of data analysis may explain some of the variability in the reported efficacy.
The studies listed in Table 1 also used multiple Bcr-Abl  positive (p210   Bcr-Abl   , p185 Bcr-Abl ) and negative cell lines. For example, Thiesing et al tested a Bcr-Abl negative cell line, MO7e, and a derivative with engineered p210
Bcr-Abl expression (MO7p210). Colony-forming assays using primary patient cells (chronic phase CML) were also performed. The findings in colony-forming assays confirmed the data generated in cell line proliferation assays with the exception that Only data generated using the same cell line (K562) were considered for comparison. All three investigators determined joint action using MTT proliferation assays.
(IC x ): inhibitory concentrations of drugs, at which combined activity was defined.
hydroxyurea (HU) was antagonistic when combined with imatinib in proliferation assays but the combination had enhanced antiproliferative activity in colony-forming assays.
IFN, a standard treatment option for CML patients, is not included in Table 1 , since various cell lines were tested using IFN in combination with imatinib. Thiesing et al reported additive activity at the IC 60 in K562 cells, whereas Kano et al found synergism testing KU812 and TCC-Y cells at the IC 80 .
Kano et al also tested the activity of imatinib in combination with vincristine and methotrexate. They found synergistic activity for vincristine in 3/4 of tested cell lines, but antagonism in 3/4 cell lines using methotrexate. Additional data on the pre-clinical evaluation of a variety of conventional chemotherapeutic agents were reported by Frü hauf et al. 27 All of the data for the various combinations of imatinib with conventional chemotherapy are presented in Table 2 .
A consistent observation from our studies and that of others is that increased synergy is observed at higher levels of inhibition. 22, 28 Our interpretation of this is that maximal inhibition of Bcr-Abl kinase activity is required to reverse the drugresistant phenotype induced by Bcr-Abl expression. The implication of this is that full doses of imatinib would be required to achive optimal therapeutic responses in combination regimens.
Predicting hematologic toxicity of combination regimens using pre-clinical data
Pre-clinical studies showed that imatinib is a relatively selective kinase inhibitor. Kinases inhibited at submicromolar concentrations are Abl (v-Abl, c-Abl, Tel/Abl, Bcr-Abl), PDGF-R alpha and beta, Tel/PDGF-R beta, c-Kit, Arg and Tel/Arg. [29] [30] [31] [32] Cytotoxicity studies comparing the anti-proliferative activity of imatinib against Bcr-Abl expressing cell lines compared to Bcr-Abl negative cell lines confirmed this highly specific target profile. 29, 33 Furthermore, experiments using primary bone marrow samples from CML patients and normal donors revealed a favorable therapeutic index for imatinib with only marginal toxicity toward normal early and lineage committed progenitor cells. 29, 34 Combination studies analyzing the in vitro cytotoxicity of imatinib and chemotherapeutic agents showed no potentiation of toxicity using Bcr-Abl negative cell lines or bone marrow mononuclear cells derived from healthy donors. 21, 22 Nevertheless, c-kit has an essential role in the maintenance of normal hematopoiesis (for review see Ref. 35 ). Furthermore, c-Abl has been linked to lymphoid development. 36 Thus, inhibition of c-kit by imatinib may impair hematopoiesis and inhibition of c-Abl carries the theoretical risk of impairing lymphocyte development. Thus, combination with anti-leukemic drugs could overall lead to an aggravation of hematologic side-effects. Recently, Ruchatz et al 37 presented data showing that administration of imatinib to nude mice indeed increases the sensitivity to concomitant treatment with idarubicin (IDA) as measured by mortality, bone marrow cytopenia and spleen size. In contrast, Uemura and Griffin 38 treated normal mouse bone marrow cells with imatinib ex vivo and analyzed survival using colony-forming assays after ionizing radiation, a potent pro-apoptotic stimulus. They did not find differences in the survival rate comparing imatinib treated with untreated cells, suggesting that imatinib treatment does not affect the survival of normal hematopoietic cells when exposed to concomitant stress factors such as radiation.
Translation of in vitro studies into clinical trials
A variety of dose-finding studies combining chemotherapeutic drugs with imatinib are under way to assess their clinical efficacy and toxicity. These combinations were selected for clinical trials based on pre-clinical data described above, along with existing clinical data that established the respective agents as standard treatment options for CML or Ph + ALL. Table 3 lists some of the ongoing clinical studies. Table 3 Translation of laboratory data into clinical studies 
SPOTLIGHT

Interferon-␣
Several randomized clinical studies have established IFN as a standard treatment option for CML patients. 39, 40 Since IFN in combination with imatinib has in vitro activity, we and others initiated phase I/II clinical studies in chronic phase patients. 41, 42 The major conclusion from preliminary data is that the combination treatment is feasible and high rates of hematologic and cytogenetic responses are achievable. However, the combination of imatinib with IFN produces a higher rate of hematologic toxicity. This was seen with using conventional IFN and IFN modified by pegylation (PEG-IFN). The optimal dose schedules for phase III studies have yet to be determined.
Ara-C
Additive to synergistic activity of ara-C with imatinib in preclinical studies and the proven clinical efficacy of ara-C in all stages of CML 43 prompted several clinical studies of this combination. Our institution is conducting a phase I/II combination study of low dose ara-C and imatinib. 44 Preliminary data indicate a higher toxicity profile of this combination compared to imatinib alone. Although response rates do not appear to be superior to imatinib monotherapy, longer studies using maximally tolerated doses are ongoing to define response rates. Since ara-C was shown to improve the complete hematologic and cytogenetic response rate when combined with IFN in chronic phase patients, 45 clinical investigation is also evaluating the combination of IFN/ara-C + imatinib (Table 3) .
Multi-agent chemotherapy
Several protocols combining multi-agent chemotherapy with imatinib in advanced phase CML have been initiated (see Table 3 ). A multi-center phase I/II study in Germany is enrolling patients with myeloid blast crisis investigating the combination of mitoxantrone, etoposide, ara-C and imatinib. The rationale for this study is derived from favorable clinical results for refractory AML using etoposide and mitoxantrone 46 Leukemia and the pre-clinical data for these drugs when combined with imatinib ( Table 2) . Preliminary results of a study which sequentially combines an established regimen for Ph + ALL or lymphoid blast crisis CML with imatinib maintenance have been reported. 47 The toxicity profile seems to be equivalent to chemotherapy alone, consistent with the sequential as opposed to simultaneous combination.
Longer follow-up, optimized dosing and alternative treatment schedules are necessary to determine the therapeutic efficacy of these combination regimens.
Imatinib in combination with novel antileukemic agents
The list of compounds that show activity against Bcr-Abl expressing cell lines is rapidly growing. Several recent review articles summarize information about new anti-leukemic agents that translate insights from basic science into clinical application. [48] [49] [50] [51] [52] Here we focus on in vitro data for combinations of novel agents with imatinib. In particular, we emphasize novel combinations which are moving towards phase I/II clinical studies. Table 4 gives an overview of reported in vitro data.
Arsenic trioxide (As 2 O 3 )
The success of As 2 O 3 in promyelocytic leukemia 53, 54 and the historical experience with As 2 O 3 , the active ingredient in Fowler's solution, for CML, has led to studies of As 2 O 3 in BcrAbl-positive leukemia cells. In vitro studies with clinically achievable concentrations of As 2 O 3 showed induction of apoptosis and differentiation in Ph + K562 and HL60/Bcr-Abl cells. 55 Furthermore, myelomonocytic U937 cells with enforced expression of Bcr-Abl have increased sensitivity to As 2 O 3 as compared to parental cells, suggesting that Bcr-Abl expression acts as a sensitizer for the cytotoxic activity of As 2 O 3 . 56 This finding needs to be interpreted with caution. Using paired cell lines, we have observed that Bcr-Abl can induce either sensitivity or resistance to As 2 O 3 depending on the cell type. 91 Since As 2 O 3 toxicity is modulated by intracellular glutathione levels, 57 sensitivity to As 2 O 3 may depend on the cellular environment rather than on a specific sensitiz- ing effect of Bcr-Abl. Combination studies in K562 or HL60/Bcr-Abl cells showed that the pro-apoptotic activity of imatinib is enhanced by As 2 O 3 . 58 We also observed additive to synergistic anti-proliferative activity of As 2 O 3 and imatinib in cell line assays and the combination showed substantially decreased colony formation of lineage-committed bone marrow progenitor cells derived from CML patients. 28 As 2 O 3 specifically downregulates Bcr-Abl protein expression before induction of apoptosis and this appears to be regulated at the translational level. 59 This is of interest, particularly in regards to imatinib resistance, as Bcr-Abl overexpression is associated with resistance to imatinib.
SPOTLIGHT
Leukemia
14 Based on the promising preclinical data, we are initiating a multi-center phase I/II study, that combines As 2 O 3 with imatinib for CML chronic phase patients who do not achieve a major cytogenetic response with imatinib monotherapy.
Decitabine (5-aza-2-deoxycytidine)
This cytidine analogue was initially generated to overcome ara-C resistance and was found to be a potent hypomethylating agent. 60 DNA methylation, an important epigenetic mechanism of cell regulation, has significant implications for the pathophysiology of malignancies. 61 Decitabine induces reexpression of silenced tumor suppressor genes and has direct cytotoxic effects through insertion into DNA (for review, see Ref. 62 ). We were interested in the cytotoxic activity of decitabine in combination with imatinib and found synergistic antiproliferative activity in a wide dose range. 28 Clinical data using decitabine for the treatment of CML blast crisis have shown promising results. 63 Hence, clinical phase I/II studies for the combination of imatinib and decitabine are planned.
Farnesyl transferase inhibitors
Protein farnesylation is an important post-translational modification of intracellular proteins. A multitude of proteins undergo this modification and farnesylation may be required for these proteins to function in proliferative and survival pathways. Although proteins such as ras and rhoB are targets of farnesyl transferase inhibitors (FTIs), it is not clear that all of the cellular effects of FTIs can be explained by targeting these two proteins. 64 Regardless, FTIs have anti-proliferative properties and have entered phase I studies for acute leukemias. 65 The FTI SCH66336 was shown to be active in vitro and in vivo against a murine model of Bcr-Abl-induced leukemia and prolonged survival in p190
Bcr-Abl transgenic mice without apparent side-effects. 66, 67 It also inhibited the colony formation of CML cells at nanomolar to low micromolar doses. Daley's group recently reported in vitro sensitivity of imatinibresistant Bcr-Abl-positive cell lines and cells derived from patients with imatinib resistance to this molecule. Moreover, they observed that SCH66336 sensitized cells to imatinib, even in imatinib-resistant cell lines. 68 This opens the potential to regain imatinib sensitivity after resistance has emerged. Phase I/II trials of this combination will be initiated shortly. Topaly et al 69 also reported highly synergistic activity of a different FTI (L-744832) in lymphoid blast crisis EM-3 cells and detected no cross-resistance to imatinib resistant BVI73-R and K562-R cells. This confirms the potential of this group of molecules, especially in regards to circumventing imatinib resistance.
Homoharringtonine
The cephalotaxine alkaloid homoharringtonine (HHT) has activity against CML in vitro and in vivo. Experiments with imatinib-resistant cell lines showed mixed results with crossresistance in K562-r cells while LAMA-r cells remained sensitive to HHT. 72 These results warrant further clinical investigation of HHT in combination with imatinib. Since HHT has been shown to improve the cytogenetic response rate following therapy with IFN in early chronic phase patients, 73 combination studies including imatinib and HHT Ϯ IFN in early chronic phase may be a promising strategy.
New experimental approaches
As listed in Table 4 , a variety of other agents have been tested in conjunction with imatinib in vitro. These include signal transduction inhibitors (the geldanamycin derivative 17-AGG, the MEK1/2 inhibitor PD 184352 and the tyrphostins AG490 and adaphostin), trichostatin A, a specific histone deacetylase inhibitor, the proteasome inhibitor PS341, the aminopeptidase inhibitors bestatin and actinonin, the TNF-␣-related apoptosis inducing ligand (TRAIL) and leptomycin B, a nuclear export blocker. Evolving knowledge about mechanisms of resistance to imatinib will enable targeting of specific molecular abnormalities that cause resistance. For example, point mutations in the Abl kinase domain have been observed in some relapsed patients that result in reactivation of the Bcr-Abl kinase. 12 Thus, the Bcr-Abl kinase remains a good target in these patients. Whether alternative inhibitors can be synthesized to 
Concluding remarks and future perspective
Early in the clinical development of imatinib in vitro studies of combination strategies were performed and have been translated into clinical trials. Translation of in vitro cytotoxicity studies into clinical trials is particularly important for patients with resistance to imatinib. The major pre-clinical studies that led to clinical protocols were based on cytotoxicity data using cell lines or primary CML cells. This is indeed the first step in defining combinations with potential therapeutic synergy, however, a variety of factors may lead to the over-or underestimation of the in vivo relevance of the data.
76,77 Frey 78 pointed out that 'the only certainty involved in the evaluation of joint action is that conclusions must be drawn in the face of uncertainty'. In addition, anti-leukemic effects may be due to the cellular cytotoxicity of the agents but can also arise from effects such as immunmodulation or altered gene expression as recently reported for trichostatin A and decitabine. 79, 80 To optimize our ability to predict therapeutic and biochemical synergy, reliable animal models of human diseases could be extremely helpful. Wolff and Ilaria 81 recently reported the establishment of a murine model for therapy-treated CML using imatinib. Application of this model to identify new combination partners for imatinib may improve the process of pre-clinical drug evaluation.
As mentioned above, rapid detection of clinically relevant mechanisms of resistance to imatinib may help to identify additional molecular targets, ie elevated Bcr-Abl protein levels, drug efflux, Bcr-Abl mutations, or Bcr-Abl independent signaling pathways. This approach relies on access to well characterized patient samples. We therefore emphasize the essential role of treating patients within clinical trials to optimize existing treatment options.
